Publications

Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021) by HS Sader, RE Mendes, SJ Ryan Arends, CG Carvalhaes, D Shortridge, and M Castanheira in Int J Antimicrob Agents 2023; 61(4): 106744.

In vitro Activity of Ceftaroline Against an International Collection of Kingella kingae Isolates Recovered From Carriers and Invasive Infections by JM Maher, RE Mendes, HK Huynh, EA Porsch, JW St Greme III, P Yagupsky, and J Bradley in Pediatr Infect Dis 2023; 42(3), 206-2011.

Impact of the Recent Clinical and Laboratory Standards Institute Breakpoint Changes on the Antimicrobial Spectrum of Aminoglycosides and the Activity of Plazomicin Against Multidrug-Resistant and Carbapenem-Resistant Enterobacterales From United States Medical Centers by HS Sader, RE Mendes, JH Kimbrough, V Kantro, and M Castanheira in Open Forum Infect Dis 2023; 10 (2), ofad058.

Trends of β-Lactamase Occurrence Among Escherichia coli and Klebsiella pneumoniae in United States Hospitals During a 5-Year Period and Activity of Antimicrobial Agents Against Isolates Stratified by β-Lactamase Type by M Castanheira, JH Kimbrough, S DeVries, RE Mendes, and HS Sader in Open Forum Infect Dis 10(2): 2023, ofad038.

Changing Epidemiology of Carbapenemases Among Carbapenem-Resistant Enterobacterales From United States Hospitals and the Activity of Aztreonam-Avibactam Against Contemporary Enterobacterales (2019–2021) by HS Sader, RE Mendes, CG Carvalhaes, JH Kimbrough, M Castanheira in Open Forum Infect Dis 10.2 (2023), ofad046.

Performance of the Vitek 2 Advanced Expert System (AES) as a Rapid Tool for Reporting Antimicrobial Susceptibility Testing (AST) in Enterobacterales from North and Latin America by CG Carvalhaes, D Shortridge, LN Woosley, N Gurung, and M Castanheira in Microbiol Spectr 11(1): 2023, 046673-22.

Antifungal Activity of Isavuconazole and Comparator Agents against Contemporaneous Mucorales Isolates from USA, Europe, and Asia-Pacific by CG Carvalhaes, PR Rhomberg, MD Huband, MA Pfaller, and M Castanheira in J Fungi (Basel) 9: 241, 2023.

In Vitro Selection of Enterobacter cloacae with Cefepime, Meropenem, and Ceftazidime-Avibactam Generates Diverse Resistance Mechanisms by M Castanheira, J Lindley, TB Doyle, AP Davis, HS Sader in Int J Antimicrob 61 (2023), 106698.

The plethora of resistance mechanisms in Pseudomonas aeruginosa: transcriptome analysis reveals a potential role of lipopolysaccharide pathway proteins to novel β-lactam/ β-lactamase inhibitor combinations by M Castanheira, TB Doyle, CM Hubler, TD Collingsworth, S DeVries, RE Mendes in J Glob Antimicrob Resist 31 (2022), 72-79.

Update on the in vitro activity of ceftaroline against Staphylococcus aureus from United States (US) medical centers stratified by infection type (2018-2020) by HS Sader, M Castanheira, LR Duncan, RE Mendes in Diagn Microbiol Infect Dis 105:1 (2023), 115820.

Activities of Manogepix and Comparators against 1,435 Recent Fungal Isolates Collected during an International Surveillance Program (2020) by MA Pfaller, MD Huband, PR Rhomberg, PA Bien, and M Castanheira in Antimicrob Agents Chemother 66:100 (2022), aac.01028-22.

Activity of SPR206 and Comparator Agents Against Pseudomonas aeruginosa and Acinetobacter baumannii Causing Infections in United States Hospitals. Lead Author: Rodrigo E. Mendes. Presented at IDWeek 2022, October 19-23, Washington DC.

Multicentre validation of a modified EUCAST MIC testing method and development of associated epidemiologic cut-off (ECOFF) values for rezafungin by Arendrup MC, Arikan-Akdagli S, Castanheira M, Guinea J, Locke JB, Meletiadis J, Zaragoza O in J. Antimicrob. Chemother. (2022); dkac373.

In vitro Activity of Tebipenem against Various Resistant Subsets of Escherichia coli Causing Urinary Tract Infections in the United States (2018 to 2020) by Mendes RM, Hubler C, Kimbrough JH, Critchley I, Cotroneo N, Castanheira in Antimicrob. Agents Chemother. 66:10 (2022); aac.01214-22.

Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018–19) by Sader HS, Mendes RE, Duncan LR, Carvalhaes CG, and Castanheira M in J. Antimicrob. Chemother. 77 (2022); 2642-2649.

Evaluation of the Post-Antifungal Effect of Rezafungin and Micafungin against Candida albicans, Candida parapsilosis and Candida glabrata by Carvalhaes CG, Rhomberg PR, Pfaller MA, Locke JB, Castanheira M in Mycoses 65 (2022); 1040-1044.

Induction of Resistance Against Antipseudomonal Agents: Comparison of Novel β-Lactam/β-Lactamase Inhibitor Combinations and Other
β-Lactam Agents. Lead author: Mariana Castanheira. IDWeek 2022. October 19-21. Washington DC.

Antimicrobial Activity of Aztreonam-Avibactam Against Enterobacterales Causing Infection in United States Hospitals (2019–2021). Lead Author: Helio Sader, IDWeek 2022, October 19-21, Washington DC.

In Vitro Activity of Cefiderocol and Comparator Agents Against Molecularly Characterized Clinical Isolates of Enterobacterales Causing Infections in United States Hospitals (2020–2021). Lead author: Rodrigo Mendes, IDWeek 2022, October 19-21, Washington DC.

In vitro Activity of SPR206 and Comparator Compounds against Enterobacterales Isolates Responsible for Infections in United States Hospitals. Lead author: Rodrigo Mendes. Presented at IDWeek 2022. October 19-21, 2022. Washington DC.

Oritavancin Activity Against Gram-Positive Pathogens Causing Bloodstream Infections in Hematology/Oncology and Transplant Units
in US Medical Centers (2010–2019). Lead Author: Cecilia Carvalhaes, IDWeek 2022, October 19-21, Washington DC.

Antimicrobial Activity of Ceftibuten-Avibactam against a Global Collection of Enterobacterales from Patients with Complicated Urinary Tract Infections (2021). Lead author: Helio Sader, IDWeek 2022, October 19-21, Washington DC.

Trends in the Susceptibility of US Acinetobacter baumannii-calcoaceticus Species Complex and Stenotrophomonas maltophilia Isolates to Minocycline, 2014–2021. Lead author: Dee Shortridge, IDWeek 2022, October 19-23, Washington DC.

Aztreonam-Avibactam Activity against a Large Collection of Carbapenem-Resistant Enterobacterales (CRE) Collected in Hospitals from Europe, Asia, and Latin America (2019–2021). Lead author: Helio Sader, IDWeek 2022, October 19-21, Washington DC.

Rezafungin Activity against Candida spp. and Aspergillus spp. Isolates Causing Invasive Infections Worldwide in 2021. Lead author: Cecilia Carvalhaes, IDWeek 2022, October 19-21, Washington DC.

Activity of Gepotidacin Tested Against Molecularly Characterized Escherichia coli Isolates Resistant to Commonly Used Oral Therapies for UTI in the US (2019–2020). Lead author: Rodrigo Mendes, IDWeek 2022, October 19-21, Washington DC.

Frequency and Antimicrobial Susceptibility of Gram-negative Bacteria Isolated from Patients with Bloodstream Infections in United States (US) Medical Centers (2020–2021). Lead author: Helio Sader, IDWeek 2022, October 19-23, Washington DC.

Cefiderocol In vitro Activity Against Molecularly Characterized Pseudomonas aeruginosa and Acinetobacter baumannii-calcoaceticus Complex Clinical Isolates Causing Infection in United States Hospitals (2020–2021). IDWeek 2022. October 19-21, 2022. Washington DC.

Activity of Novel β-Lactam/β-Lactamase Inhibitor Combinations Against AmpC-Producing Species Collected in United States Hospitals. Lead Author: Mariana Castanheira, IDWeek 2022, October 19-21, Washington DC.

Dual VIM-Producing Proteus mirabilis, Including a Novel VIM-75, Among Elderly Patients in a Medical Center from Hungary: Report from the 2020 SENTRY Antimicrobial Surveillance Program. Lead Author: Gauri Deshpande; Presented by: Mariana Castanheira, IDWeek 2022, October 19-21, Washington DC.

Comparative Activity of Newer β-Lactam/β-Lactamase Inhibitor Combinations against Pseudomonas aeruginosa Isolates from United States Medical Centers (2020-2021). Lead Author: HS Sader at IDWeek 2022, October 19-23, Washington DC.

In Vitro Activity of Manogepix Against 2,810 Fungal Isolates from the SENTRY Surveillance Program (2020–2021) Stratified by Infection Type. Lead Author: Mike Huband, IDWeek 2022, October 19-21, Washington DC.

Antimicrobial Activity of Ceftibuten-Avibactam against a Global Collection of Enterobacterales from Patients with Complicated Urinary Tract Infections (2021). Lead author: Helio Sader, IDWeek 2022, October 19-21, Washington DC.

In Vitro Activity of Isavuconazole and Other Mould-Active Triazoles Against Aspergillus fumigatus With and Without cyp51 Alterations. Lead Author: Cecilia Carvalhaes, IDWeek 2022, October 19-21, Washington DC.

Increase in the Occurrence of Carbapenem-Resistant Enterobacterales in United States Hospitals from 2019 to 2021 and Activity of Novel β-Lactam/
β-Lactamase Inhibitor Combinations Against These Isolates. Lead author: Mariana Castanheira, IDWeek 2022, October 19-21, Washington DC.

Activity of Gepotidacin Against Escherichia coli Isolates from Community-acquired Urinary Tract Infections Collected Between 2019-2021 in the
United States. Lead Author: Rodrigo Mendes. IDWeek 2022. October 19-21, 2022. Washington DC.

Antimicrobial Activity of Aztreonam-Avibactam Against a Large Collection of Stenotrophomonas maltophilia and Burkholderia cepacia Species Complex Causing Infections in United States (US) Medical Centers (2016–2021). Lead Author: Helio Sader, IDWeek 2022, October 19-21, Washington DC.

In Vitro Evaluation of Delafloxacin Activity Against Contemporary US Isolates from Cystic Fibrosis Patients Hospitalized with Pneumonia: Results from the SENTRY Antimicrobial Surveillance Program (2019–2021). Lead author: Dee Shortridge, IDWeek 2022, October 19-23, Washington DC.

Activity of Oritavancin and Comparator Agents Against Coagulase-Negative Staphylococci Causing Bloodstream Infections in US Medical Centers (2017-2019). Lead author: Cecilia G Carvalhaes, IDWeek 2022, October 19-23, Washington DC.

Activity of Meropenem-Vaborbactam and Comparators AgainstEnterobacterales Isolates from Patients in Hematology/Oncology and Transplant Units in the United States. Lead author: Dee Shortridge, IDWeek 2022, October 19-23, Washington DC.

Antimicrobial Activity of Aztreonam-Avibactam, Ceftazidime-Avibactam, and Comparator Agents against Pseudomonas aeruginosa from Cystic
Fibrosis Patients. Lead Author: Helio Sader, IDWeek 2022, October 19-21, Washington DC.

Prevalence, Phenotypic and Genotypic Characteristics, and Clinical Presentations of Staphylococcus argenteus Causing Bloodstream Infections in United States Hospitals. Lead author: Rodrigo Mendes, IDWeek 2022, October 19-21, Washington DC.

In Vitro Evaluation of Delafloxacin Activity Against Contemporary US Isolates from Cystic Fibrosis Patients Hospitalized with Pneumonia: Results from the SENTRY Antimicrobial Surveillance Program (2019–2021). Lead author: Dee Shortridge, IDWeek 2022, October 19-21, Washington DC.

Antimicrobial Activity of Ceftazidime-Avibactam and Other New β-Lactamase Inhibitor Combinations Tested against Bacterial Isolates from Pediatric
Patients from US Medical Centers (2020–2021). Lead author: Helio Sader. IDWeek 2022. October 19-21. Washington DC.

Azole Activity against Filamentous Fungi Causing Invasive Infections in Patients from ICU and Non-ICU Units (2017–2021). Lead author: Cecilia Carvalhaes, IDWeek 2022, October 18-21, Washington DC.

In Vitro Activity of Omadacycline against 14,000 Bacterial Isolates from the United States by Infection Type (2020–2021). Lead Author: Michael Huband, IDWeek 2022, October 19-21, Washington DC.

Prevalence of carbapenemase genes among carbapenem-nonsusceptible Enterobacterales collected in US hospitals in a five-year period and activity of ceftazidime/avibactam and comparator agents by Castanheira M, Deshpande LM, Mendes RE, Doyle TB, Sader HS in JAC-Antimicrob. Resist. 2022; 4(5): dlac098.

Activity of Meropenem/Vaborbactam and Comparators against non-carbapenemase producing carbapenem-resistant Enterobacterales isolates from Europe by Shortridge D, Deshpande L, Streit J, and Castanheira M in JAC – Antimicrob. Resist. 2022; 4 (5): dlac097.

Tedizolid in vitro activity against Gram-positive clinical isolates causing bone and joint infections in hospitals in the USA, Europe, Latin America, and the Asia-Pacific region (2015-2019) by Pfaller MA, Mendes RE, Streit JM, Carvalhaes, CG in Diagnostic Microbiology and Infectious Disease 2022; 104: 115804.

Antimicrobial Activity of Ceftaroline and Comparator Agents Against Ceftriaxone-Nonsusceptible Streptococcus pneumoniae from the United States (2008-2020) by Sader HS, Castanheira M, Carvalhaes CG, Arends SJR, Mendes RE in Microbial Drug Resistance 2022; 28 (9): 935-940.